Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath^®) in patients with chronic lymphocytic leukaemia and its link to treatment response

Alemtuzumab displayed time- and concentration-dependent pharmacokinetics with large interpatient variability, both in pharmacokinetics and pharmacodynamics, which was probably reflective of differences in tumour burden among patients. A direct relationship between maximal trough concentrations and clinical outcomes was observed, with increasing alemtuzumab exposure resulting in a greater probability of positive tumour response.